Previous 10 | Next 10 |
2023-08-09 10:08:11 ET Gainers: Tango Therapeutics ( TNGX ) +137% . Decibel Therapeutics ( DBTX ) +72% . Mirati Therapeutics ( MRTX ) +26% . Azenta ( AZTA ) +25% . Clover Health Investments ( CLOV ) +18 % . Losers: ...
2023-08-07 07:19:02 ET Tango Therapeutics press release ( NASDAQ: TNGX ): Q2 GAAP EPS of -$0.23 beats by $0.08 . Revenue of $14.6M (+152.6% Y/Y) beats by $7.65M . For further details see: Tango Therapeutics GAAP EPS of -$0.23 beats by $0.08, revenue of $1...
– First patient dosed in phase 1/2 trial of TNG462, a next-generation PRMT5 inhibitor for the treatment of MTAP-deleted tumors – – Dose escalation ongoing in phase 1/2 trial of TNG908, a novel brain-penetrant PRMT5 inhibitor for the treatment of MTAP-deleted tumors ...
2023-07-27 08:38:02 ET Mersana Therapeutics ( MRSN ) -74% announces topline data from UPLIFT clinical trial in patients with platinum-resistant Ovarian Cancer and strategic reprioritization. Biohaven ( BHVN ) -27% . Yellow Corporation ( YELL ) -26% . ...
2023-07-26 19:29:51 ET Summary In my previous article, I hoped that Tango publishing POC data would help the stock. They published partial data, and it was not convincing. The stock remains stagnant. I was hoping for some spike on early data update from TNG908, a...
BOSTON, July 24, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial evaluat...
BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the phase 1/2 trial of TNG462 in patients ...
2023-05-09 08:54:19 ET Tango Therapeutics press release ( NASDAQ: TNGX ): Q1 GAAP EPS of -$0.32 beats by $0.03 . Revenue of $5.77M (+0.2% Y/Y) misses by $1M . For further details see: Tango Therapeutics GAAP EPS of -$0.32 beats by $0.03, revenue of $5.77M...
– Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatmen...
2023-04-23 23:47:25 ET The following slide deck was published by Tango Therapeutics, Inc. in conjunction with this event. For further details see: Tango Therapeutics (TNGX) Investor Presentations - Slideshow
News, Short Squeeze, Breakout and More Instantly...
Tango Therapeutics Inc. Company Name:
TNGX Stock Symbol:
NASDAQ Market:
2024-06-25 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-15 03:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present...